News

Dosing Begins in Phase 2a Trial of Oral Treatment to Aid Cognition

Patient dosing has begun in a Phase 2a clinical trial testing oral CST-2032 in combination with CST-107 as a potential way to ease the symptoms of mild cognitive impairment and mild dementia due to Parkinson’s or Alzheimer’s disease, the company developing these therapies, CuraSen Therapeutics, announced. The trial (…

APDA Funds $2.35M in New ‘Cutting-edge’ Parkinson’s Research

The American Parkinson Disease Association (APDA) will fund a host of Parkinson’s disease research projects for the coming year, including one that will examine the molecular underpinnings of anxiety and another that proposes a treatment for freezing of gait, for a total funding package of $2.35 million, a 25%…

Dopamine Agonists Linked to Poorer Blood Vessel Function

Rates of blood vessel dysfunction are not significantly different in people with Parkinson’s disease compared to the general population, a small study reports. The findings indicate that, among people with Parkinson’s, smoking and the use of treatments called dopamine agonists are associated with poorer blood vessel function. The…

Irisin Hormone Shows Potential as Parkinson’s Treatment

The hormone irisin prevents the buildup of toxic alpha-synuclein protein, leading to the preservation of nerve cells and easing motor symptoms in a mouse model of Parkinson’s disease, a study has found. Experiments showed the hormone had an ability to facilitate the breakdown of toxic alpha-synuclein through lysosomes, the…

Tau Protein Buildup in Nerve Cells Prompts Neurodegeneration

A protein “traffic jam” inside nerve cells promotes the buildup of shorter and toxic tau — a protein that forms toxic aggregates in Parkinson’s and other neurodegenerative disorders — according to a new study using fruit flies and mammalian cell lines. The accumulation of toxic tau resulted in fewer connections…

Way of Visualizing Alpha-Synuclein Clumps in Living Brain Reported

Using a newly created probe and non-invasive PET scans, researchers were able to visualize sites of alpha-synuclein protein clumps — associated with nerve damage in Parkinson’s disease — in the brains of living patients, scientists reported. This method may help in diagnosing conditions related to alpha-synuclein clumping, referred to…

Phase 2 Trial Tests DopaFuse for Continuous Oral Levodopa Delivery

SynAgile announced the completion of a Phase 2 clinical trial evaluating DopaFuse, its noninvasive system for the continuous oral delivery of levodopa/carbidopa to people with Parkinson’s disease. Sixteen adults being treated with levodopa/carbidopa (LD/CD) in a tablet form were enrolled in the open-label study into the safety and tolerability…

Alpha-synuclein Clumping Seen to Affect Mitochondria Early

Alpha-synuclein aggregation — the toxic clumping of proteins in nerve cells that is a hallmark of Parkinson’s disease — starts on the membranes of mitochondria, the so-called powerhouse of a cell, according to work in cell models. “Our study provides insights into what is happening in the earliest stages…